Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Mutant ASXL1 Promotes Expansion of the Phenotypic Hematopoietic Stem Cell Compartment

Takeshi Fujino, MD, Susumu Goyama, MD PhD, Yuki Sugiura, PhD, Daichi Inoue, MD PhD, Satoshi Yamasaki, PhD, Akiko Matsumoto, Naru Sato, MD, Hironobu Morinaga, PhD, Shiori Shikata, Tomofusa Fukuyama, MD PhD, Yosuke Tanaka, PhD, Shuhei Asada, MD PhD, Tsuyoshi Fukushima, MD PhD, Hiroaki Honda, MD PhD, Emi K Nishimura, MD PhD, Tatsuhiro Shibata, MD PhD, Makoto Suematsu, MD PhD, Toshio Kitamura, MD PhD

Blood (2019) 134 (Supplement_1): 821.

https://doi.org/10.1182/blood-2019-127904

Published: 2019

Journal Articles

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Shehroz Aslam, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Rida Riaz, MBBS, Seren Durer, MD, Ceren Durer, MD, Faisal Mahfooz, MD, Muhammad Jahanzeb Khalil, MD, Jemin Aby Jose, MD, Zunairah Shah, MBBS, Chaudhry Saad Sohail, MD, Maaz Ahmed Yusufi, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5659.

https://doi.org/10.1182/blood-2018-99-115721

Published: 2018

Journal Articles

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Imad Ud Deen, MBBS, Muhammad Umar Khalid, MD, Atlantis Dawn Russ, MD PhD, Anh Hua, BS, Ahmad Iftikhar, MD, Adeela Mushtaq, MD, Ahmad Safdar, BS, Ali McBride, PharmD,MS, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5399.

https://doi.org/10.1182/blood.V130.Suppl_1.5399.5399

Published: 2017

Journal Articles

Casein Kinase II Inhibition By CX-4945 and Epigenetic Modulation By Decitabine Demonstrate Significant Antiproliferative Activity As Single Agents As Well As in Combination in Acute B-Lymphoblastic Leukemia Cells

Anna Richter, Catrin Roolf, PhD, Sina Sender, M.Sc., Weibo Kong, M.Sc., Gudrun Knübel, Anett Sekora, Yvonne Saara Gladbach, M.Sc., Mohamed Hamed, PhD, Georg Fuellen, PhD, Brigitte Vollmar, MD, Irmela Jeremias, Jens P. Panse, MD, Hugo Murua Escobar, PhD, Christian Junghanss, MD

Blood (2017) 130 (Supplement 1): 3887.

https://doi.org/10.1182/blood.V130.Suppl_1.3887.3887

Published: 2017

Journal Articles

Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients

Anna Guidetti, MD, Simonetta Viviani, MD, Anna Dodero, MD, Lucia Farina, MD, Domenico Russo, MD PhD, Pietro Bulian, Massimo Di Nicola, MD, Arabella Mazzocchi, MD, Fernando Ravagnani, MD, Paolo Corradini, MD, Alessandro Massimo Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2014) 124 (21): 4459.

https://doi.org/10.1182/blood.V124.21.4459.4459

Published: 2014

Journal Articles

LAT2, a Lipid Raft Protein That Participates in AKT Phosphorylation in Mantle Cell Lymphoma, Is a Target for Perifosine Chemotherapy

Germano A Ferreira, PhD, Carolina H Thomé, PhD, Priscila Santos Scheucher, PhD, Andréia M Leopoldino, Prof. PhD, Ana Maria Simão, PhD, Clarice Izumi, PhD, Pietro Ciancaglini, Prof. PhD, Vitor Marcel Faça, Prof, PhD, Lewis Joel Greene, Prof. PhD, Guilherme A Santos, MD PhD, Eduardo M Rego, Prof, MD PhD

Blood (2014) 124 (21): 923.

https://doi.org/10.1182/blood.V124.21.923.923

Published: 2014

Journal Articles

The PI3K/ERK Dual Inhibitor AEZS-136 Induces ROS-Dependent Necroptotic Cell Death and Exerts Potent Antitumor Effects In NOD/SCID Mice With Hodgkin Lymphoma Cell Line Xenografts

Silvia L Locatelli, PhD, Giuliano G Stirparo, Silvia Tartari, PhD, Elena Saba, PhD, Luca Rubino, PhD, Ercole Brusamolino, MD, Luca Castagna, MD, Armando Santoro, MD, Carmelo Carlo-Stella, MD

Blood (2013) 122 (21): 3067.

https://doi.org/10.1182/blood.V122.21.3067.3067

Published: 2013

Journal Articles

Inhibition Of PI3K/mTOR By BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality In Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms

Mohamed Rahmani, Ph.D, Mandy Aust, MS, LaShanale Wallace, BS, Steven Grant, MD

Blood (2013) 122 (21): 817.

https://doi.org/10.1182/blood.V122.21.817.817

Published: 2013

Journal Articles

Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib

Blood (2013) 122 (21): 3189.

https://doi.org/10.1182/blood.v122.21.3189.3189

Published: 2013

Journal Articles

Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms

Santiago Barrio, Miguel Gallardo, Alicia Arenas, Rosa M. Ayala, MD, PhD, Inmaculada Rapado, Daniel Rueda, PhD, Ana Jimenez, Enriqueta Albizua, Carmen Burgaleta, Florinda Gilsanz, MD, PhD, Joaquin Martinez, MD

Blood (2012) 120 (21): 5054.

https://doi.org/10.1182/blood.V120.21.5054.5054

Published: 2012

Journal Articles

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Anna Guidetti, MD, Simonetta Viviani, MD, Alfonso Marchianò, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Silvia L Locatelli, PhD, Domenico Russo, Pietro Bulian, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Laura Giordano, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2012) 120 (21): 3679.

https://doi.org/10.1182/blood.V120.21.3679.3679

Published: 2012

Journal Articles

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Klaus Martin Kortuem, MD, Steven R Schuster, MD, Meaghan L. Khan, MD, Kaitlyn E. Zidich, Victor H Jimenez-Zepeda, MD, Rafael Fonseca, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4034.

https://doi.org/10.1182/blood.V120.21.4034.4034

Published: 2012

Journal Articles

Combination of NVP-BEZ235 and Enzastaurin on B-Cell Lymphoma Cell Lines: An Effective Therapeutic Strategy

Monica Civallero, Maria Cosenza, Samantha Pozzi, MD, Stefano Sacchi, MD

Blood (2011) 118 (21): 2719.

https://doi.org/10.1182/blood.V118.21.2719.2719

Published: 2011

Journal Articles

Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,

Anna Guidetti, MD, Silvia Locatelli, PhD, Simonetta Viviani, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Domenico Russo, Pietro Bulian, Roberto Sorasio, MD, Massimo Di Nicola, MD, Paolo Corradini, MD, Andrea Anichini, PhD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2011) 118 (21): 3705.

https://doi.org/10.1182/blood.V118.21.3705.3705

Published: 2011

Journal Articles

PIM2 Upregulation Leads to Physiological Buffering of Metformin-Induced Cell Death Mediated by ER Stress/UPR in Acute Lymphoblastic Leukemia,

Gilles M. Leclerc, Ph.D., Guy J. Leclerc, Ph.D., Jeffim N. Kuznetsov, B.Sc., Julio C. Barredo, M.D.

Blood (2011) 118 (21): 3496.

https://doi.org/10.1182/blood.V118.21.3496.3496

Published: 2011

Journal Articles

Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial

Blood (2011) 118 (21): 815.

https://doi.org/10.1182/blood.V118.21.815.815

Published: 2011

Journal Articles

Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study

Shaji Kumar, MD, William I Bensinger, MD, Craig B. Reeder, MD, Todd M. Zimmerman, MD, James R. Berenson, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Neeraj Gupta, PhD, Alessandra Di Bacco, PhD, Ai-Min Hui, MD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 816.

https://doi.org/10.1182/blood.V118.21.816.816

Published: 2011

Journal Articles

Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk Myelodysplastic Syndromes (MDS)

Kelly J. Norsworthy, MD, Alexander E Perl, MD, Martin Carroll, MD, Selina M. Luger, MD, Kenneth S. Bauer, PharmD, PhD, Michael L. Tidwell, CRNP, Dina Ioffe, BA, Maria R. Baer, MD, Edward A. Sausville, MD, PhD, Ivana Gojo, MD

Blood (2011) 118 (21): 1557.

https://doi.org/10.1182/blood.V118.21.1557.1557

Published: 2011

Journal Articles

Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma

Silvia Locatelli, PhD, Arianna Giacomini, PhD, Anna Guidetti, MD, Loredana Cleris, PhD, Michele Magni, MD, Massimo Di Nicola, MD, Roberta Mortarini, PhD, Alessandro M Gianni, MD, Andrea Anichini, PhD, Carmelo Carlo-Stella, MD

Blood (2011) 118 (21): 1653.

https://doi.org/10.1182/blood.V118.21.1653.1653

Published: 2011

Journal Articles

Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)

Andrzej J Jakubowiak, MD, PhD, Paul G Richardson, MD, Todd M Zimmerman, MD, Melissa Alsina, MD, Jonathan L. Kaufman, MD, Malathi Kandarpa, PhD, Colleen K. Harvey, Kathleen Colson, RN, BSN, BS, Monica Mitchell, RN, OCN, Teru Hideshima, MD, PhD, Peter Sportelli, Lesa Gardner, RN, Kathy Giusti, MBA, Kenneth C. Anderson, MD

Blood (2010) 116 (21): 3064.

https://doi.org/10.1182/blood.V116.21.3064.3064

Published: 2010

NARROW

Mutant ASXL1 Promotes Expansion of the Phenotypic Hematopoietic Stem Cell Compartment

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Casein Kinase II Inhibition By CX-4945 and Epigenetic Modulation By Decitabine Demonstrate Significant Antiproliferative Activity As Single Agents As Well As in Combination in Acute B-Lymphoblastic Leukemia Cells

Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients

LAT2, a Lipid Raft Protein That Participates in AKT Phosphorylation in Mantle Cell Lymphoma, Is a Target for Perifosine Chemotherapy

The PI3K/ERK Dual Inhibitor AEZS-136 Induces ROS-Dependent Necroptotic Cell Death and Exerts Potent Antitumor Effects In NOD/SCID Mice With Hodgkin Lymphoma Cell Line Xenografts

Inhibition Of PI3K/mTOR By BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality In Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms

Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib

Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Combination of NVP-BEZ235 and Enzastaurin on B-Cell Lymphoma Cell Lines: An Effective Therapeutic Strategy

Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,

PIM2 Upregulation Leads to Physiological Buffering of Metformin-Induced Cell Death Mediated by ER Stress/UPR in Acute Lymphoblastic Leukemia,

Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial

Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study

Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk Myelodysplastic Syndromes (MDS)

Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma

Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only